Pharma Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA panel recommends approval of Rituxan biosimilar

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.